Trials / Completed
CompletedNCT02542696
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 496 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APL-130277 | Used to treat up to 5 "OFF" episodes per day |
Timeline
- Start date
- 2015-08-31
- Primary completion
- 2022-11-08
- Completion
- 2022-11-08
- First posted
- 2015-09-07
- Last updated
- 2023-11-22
- Results posted
- 2023-11-22
Locations
70 sites across 8 countries: United States, Austria, Canada, France, Germany, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02542696. Inclusion in this directory is not an endorsement.